Bayer Aktiengesellschaft (0P6S.L)
| Previous close | 57.95 |
| Open | 58.54 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 56.91 - 57.16 |
| 52-week range | 46.72 - 65.65 |
| Volume | |
| Avg. volume | 841,216 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Bayer CEO: Now is not the time to break the company up
Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now. Bayer CEO Bill Anderson says, "This is not a good time to be... breaking up the firm," given the company's need to rebuild its pharmaceutical pipeline and battle the ongoing litigation stemming from the weedkiller Roundup. When it comes to the Roundup lawsuits, Bayer has "adequately provisioned" for the costs of those suits, Anderson says. Overall, "the fundamental fact is, that glyphosate, Roundup, is safe," Anderson states, adding that Bayer is "a scientifically-driven company and we have this litigation thing that's not scientific." On the pharmaceutical business, Anderson says the group is "in a bit of a transition phase." "We got a couple of major medicines that are losing patent protection over the next few years. So we are busy rebuilding the pipeline right now," he tells Yahoo Finance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.
- Yahoo Finance Video
Inflation: Over-the-counter drug prices leap year over year
Alongside other sectors of the consumer economy, nonprescription drug prices saw prices rise 9.3% year-over-year. The insurance industry, health insurance and auto insurance providers in particular, have been beset by inflationary challenges. Yahoo Finance Health Reporter Anjalee Khemlani details the price trends for over-the-counter drugs, referencing a statement from Bayer (BAYRY) from its third-quarter 2023 in relation to how pharmaceutical companies are trying to offset inflation. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.
- Yahoo Finance Video
Bayer stock plunges after drug trial halted
Bayer (BAYRY) shares closed 17% lower on Monday after the company halted a trial for a blood-thinning drug due to "lack of efficacy." The news sent shares of Bristol Myers Squibb (BMY) lower because it's developing a similar drug. Also impacting Bayer shares is the news that the company was ordered to pay $1.56 billion in a lawsuit involving its Roundup weedkiller. Yahoo Finance Live breaks down the stock action. Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here.
